This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Padma Malyala
Vice President, Formulation and Analytical Development at Verve Therapeutics


Padma Malyala is Vice President, Formulation and Analytical Development at Verve Therapeutics. She has nearly 20 years’ experience in formulation and characterization of complex biotherapeutics at Novartis, GSK and MedImmune-AstraZeneca. Most recently, Ms. Malyala served as head of the formulation and characterization group for Biologics at Novartis Institute for Biomedical Research (NIBR), where she was responsible for de-risking the development process and transition well defined robust drug products to the clinic. She was also a key member of due diligence teams to strengthen the drug product science, as well as the immuno- oncology portfolio. As global head, pharmaceutical sciences in technical R&D at GSK, she managed technology transfer of the RNA-LNP platform technology to development, using QbD principles. Previously, Ms. Malyala served as group leader, formulations at MedImmune – AstraZeneca and as global head-pharmaceutical sciences at Novartis Vaccines. She is the author of multiple patents, publications and book chapters in the field of formulation, characterization and delivery systems. Ms. Malyala received both her B.S. in Pharmaceutical Sciences and M.S. in Pharmaceutical Chemistry (Gold Medalist) from Andhra University in India.

Agenda Sessions

  • Innovative LNPs for Gene Editing Applications